Long acting GLP-1 receptor agonist (injectable)
Efpeglenatide 12 mg injection every 4 weeks
EFPE_SC_12MG_Q4W
Related
- All doses pooled: Efpe sc
- Efpe sc 1mg qw
- Efpeglenatide 2 mg subcutaneous once weekly
- Efpeglenatide 4 mg subcutaneous once weekly
- Efpe sc 8mg qm
- Efpe sc 12mg qm
- Efpeglenatide 16 mg injection monthly
- Efpeglenatide 8 mg injection every 4 weeks
- Efpeglenatide 16 mg injection every 4 weeks
- Efpeglenatide 6 mg subcutaneous once weekly
- Efpeglenatide 6 mg injection every 2 weeks
- Efpeglenatide 8 mg injection every 2 weeks
Effects across outcomes
Bayesian random effects estimate against the comparator of each analysis (usually placebo), posterior median and 95% credible interval. Green: clearly better; red: clearly worse.
| Condition | Outcome | Window | Versus | Effect (95% CrI) | SUCRA |
|---|---|---|---|---|---|
| Type 2 diabetes (adults) | Level 2 or 3 hypoglycemia (participants) | longest follow-up | Placebo | HR 0.64 (0.01 to 43.28) | 0.67 |
| Type 2 diabetes (adults) | Serious adverse events | longest follow-up | Placebo | HR 2.74 (0.62 to 15.10) | 0.19 |
| Type 2 diabetes (adults) | Discontinuation due to adverse events | longest follow-up | Placebo | HR 4.32 (0.99 to 24.07) | 0.24 |
| Type 2 diabetes (adults) | Nausea | longest follow-up | Placebo | HR 14.89 (4.38 to 69.83) | 0.06 |
| Type 2 diabetes (adults) | Vomiting | longest follow-up | Placebo | HR 5.16 (1.55 to 22.27) | 0.30 |
| Type 2 diabetes (adults) | Diarrhea | longest follow-up | Placebo | HR 1.85 (0.56 to 6.23) | 0.44 |
| Type 2 diabetes (adults) | Acute pancreatitis | longest follow-up | Placebo | HR 0.87 (0.05 to 12.25) | 0.47 |